Marijuana companies OrganiGram and Aphria reported their most recent quarterly earnings earlier this week. One of the companies reported surprisingly strong sales, while the other delivered disappointment.
Lingering trade spats and fears of a global economic slowdown stunted corporate deal-making worldwide during the first quarter. Large, international deals that drove the acquisitions market for years disappeared,
Bristol-Myers approval follows an unsuccessful activist campaign to undo the deal Bristol-Myers Squibb shareholders on Friday approved the company’s $74 billion acquisition of rival Celgene Corp., looking
NEW YORK (Reuters) - Bristol-Myers Squibb Co's shareholders voted to approve the drugmaker's $74 billion acquisition of biotech Celgene Corp on Friday despite a campaign by activist hedge fund Starboard